

Sigurdur Yngvi Kristinsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4772405/publications.pdf>

Version: 2024-02-01

142
papers

10,944
citations

36271

51
h-index

31818

101
g-index

143
all docs

143
docs citations

143
times ranked

11473
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. <i>Haematologica</i> , 2022, 107, 284-286.	1.7	4
2	The first wave of COVID-19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric well-being. <i>Journal of Internal Medicine</i> , 2022, 291, 837-848.	2.7	1
3	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	0.9	4
4	Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance. <i>Frontiers in Immunology</i> , 2022, 13, 876271.	2.2	9
5	A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. <i>European Journal of Haematology</i> , 2021, 106, 346-353.	1.1	5
6	Comorbidities in multiple myeloma and implications on survival: A population-based study. <i>European Journal of Haematology</i> , 2021, 106, 774-782.	1.1	18
7	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
8	Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. <i>European Journal of Haematology</i> , 2021, 107, 137-144.	1.1	2
9	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. <i>Blood Cancer Journal</i> , 2021, 11, 94.	2.8	52
10	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 275-282.	1.1	8
11	Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population. <i>BMJ Open</i> , 2021, 11, e049967.	0.8	6
12	Genetic variants associated with platelet count are predictive of human disease and physiological markers. <i>Communications Biology</i> , 2021, 4, 1132.	2.0	7
13	Survival, Causes of Death, and the Prognostic Role of Comorbidities in Chronic Lymphocytic Leukemia in the pre-ibrutinib era. A Population Based Study. <i>European Journal of Haematology</i> , 2021, , .	1.1	3
14	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	1.1	6
15	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). <i>Blood</i> , 2021, 138, 154-154.	0.6	0
16	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 191.	2.8	7
17	Validity of chronic disease diagnoses in Icelandic healthcare registries. <i>Scandinavian Journal of Public Health</i> , 2021, , 140349482110599.	1.2	4
18	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. <i>Thrombosis Research</i> , 2020, 186, 86-92.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. <i>European Journal of Haematology</i> , 2020, 104, 376-382.	1.1	8
20	Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. <i>Haematologica</i> , 2020, 105, 2679-2681.	1.7	11
21	A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival. <i>European Journal of Haematology</i> , 2020, 105, 547-554.	1.1	2
22	Fractures and survival in multiple myeloma: results from a population-based study. <i>Haematologica</i> , 2020, 105, 1067-1073.	1.7	29
23	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
24	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	3.4	57
25	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>British Journal of Haematology</i> , 2019, 186, 37-44.	1.2	0
26	Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. <i>Blood</i> , 2019, 134, 5444-5444.	0.6	1
27	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , 2018, 168, 317.	2.0	177
28	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. <i>Leukemia</i> , 2018, 32, 2203-2210.	3.3	64
29	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	1.7	87
30	Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	1.7	103
31	Dietary intake is associated with risk of multiple myeloma and its precursor disease. <i>PLoS ONE</i> , 2018, 13, e0206047.	1.1	19
32	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	5.8	86
33	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , 2018, 169, 268.	2.0	12
34	Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases. <i>Blood</i> , 2018, 132, 1914-1914.	0.6	0
35	The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study. <i>Blood</i> , 2018, 132, 4490-4490.	0.6	0
36	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>Annals of Hematology</i> , 2017, 96, 261-269.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , 2017, 99, 216-222.	1.1	48
38	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS). , 2017, , 143-167.		0
39	Epidemiology of Waldenström Macroglobulinemia. , 2017, , 97-109.		1
40	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. <i>Blood Advances</i> , 2017, 1, 2392-2398.	2.5	15
41	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. <i>Blood Advances</i> , 2017, 1, 2790-2798.	2.5	23
42	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. <i>Blood Advances</i> , 2017, 1, 2186-2192.	2.5	47
43	Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. <i>Annals of Hematology</i> , 2016, 95, 871-879.	0.8	13
44	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146
45	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , 2016, 101, e145-e148.	1.7	26
46	Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. <i>BMJ Open</i> , 2016, 6, e009584.	0.8	32
47	Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 337-344.	0.8	26
48	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. <i>Blood</i> , 2016, 128, 3246-3246.	0.6	0
49	Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival. <i>Blood</i> , 2015, 125, 2174-2175.	0.6	21
50	Survival in patients with familial and sporadic myeloproliferative neoplasms. <i>Blood</i> , 2015, 125, 3665-3666.	0.6	8
51	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 168.	3.4	93
52	Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. <i>Cancer Medicine</i> , 2015, 4, 147-154.	1.3	16
53	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	1.7	356
54	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2288-2295.	0.8	106

#	ARTICLE	IF	CITATIONS
55	Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based caseâ€“control study from Sweden. <i>International Journal of Hematology</i> , 2015, 101, 563-568.	0.7	10
56	Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups. <i>Acta Haematologica</i> , 2015, 133, 372-380.	0.7	2
57	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. <i>Nature Communications</i> , 2015, 6, 7213.	5.8	101
58	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , 2014, 123, 338-345.	0.6	105
59	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
60	Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. <i>Haematologica</i> , 2014, 99, 392-398.	1.7	249
61	Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study. <i>Blood</i> , 2014, 124, 632-632.	0.6	11
62	Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenstr�m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 187-190.	0.2	8
63	Patterns of survival in lymphoplasmacytic lymphoma/waldenstr�m macroglobulinemia: A populationâ€“based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. <i>American Journal of Hematology</i> , 2013, 88, 60-65.	2.0	66
64	Etiology of Waldenstr�m Macroglobulinemia: Genetic Factors and Immune-related Conditions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 194-197.	0.2	10
65	Genetics in Lymphomagenesis. , 2013, , 835-847.		0
66	No familial aggregation in chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 460-461.	0.6	22
67	Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?. <i>Blood</i> , 2013, 122, 1946-1946.	0.6	13
68	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , 2013, 122, 1972-1972.	0.6	4
69	Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. <i>PLoS ONE</i> , 2013, 8, e79851.	1.1	23
70	Monoclonal Gammopathy Of Undetermined Significance and Risk Of Lymphoid and Myeloid Malignancies: 743 Cases Followed For Up To 30 Years In Sweden. <i>Blood</i> , 2013, 122, 3124-3124.	0.6	0
71	Multiple Myeloma Patients With Prior Knowledge Of MGUS Have a Better Survival Compared To Multiple Myeloma Patients Without Prior Knowledge Of MGUS. <i>Blood</i> , 2013, 122, 1984-1984.	0.6	0
72	Impact Of History Of Autoimmune Disease On Survival In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance: A Population-Based Study. <i>Blood</i> , 2013, 122, 1898-1898.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Familial Aggregation of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 179-183.	0.8	35
74	Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2995-3001.	0.8	182
75	Thromboprophylaxis in multiple myeloma: is the evidence there?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 291-294.	1.1	4
76	Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid Malignancies. <i>Acta Haematologica</i> , 2012, 127, 173-177.	0.7	19
77	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1603-1607.	1.7	66
78	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	1.7	110
79	Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. <i>Blood</i> , 2012, 119, 990-996.	0.6	69
80	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , 2012, 119, 2731-2737.	0.6	108
81	Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. <i>International Journal of Cancer</i> , 2012, 131, 2208-2209.	2.3	14
82	Re: Risk of malignancy associated with Lyme disease: Still up in the air. <i>International Journal of Cancer</i> , 2012, 131, 2718-2718.	2.3	0
83	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 945-945.	0.6	2
84	The association of cancer and venous thrombosis: yes, Trousseau is right â€¦ again!. <i>Leukemia and Lymphoma</i> , 2011, 52, 734-735.	0.6	1
85	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , 2011, 117, 5573-5581.	0.6	161
86	What Causes Waldenström's Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 85-87.	0.2	10
87	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 593-603.	1.5	35
88	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. <i>Seminars in Hematology</i> , 2011, 48, 46-54.	1.8	13
89	Infection in infancy and subsequent risk of developing lymphoma in children and young adults. <i>Blood</i> , 2011, 117, 1670-1672.	0.6	8
90	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	0.6	74

#	ARTICLE	IF	CITATIONS
91	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). <i>Blood</i> , 2011, 118, 4086-4092.	0.6	173
92	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , 2011, 128, 2688-2694.	2.3	59
93	Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. <i>Journal of Clinical Oncology</i> , 2011, 29, 2514-2520.	0.8	183
94	Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2011, 29, 2897-2903.	0.8	239
95	Cancer Risk Among Patients With Myotonic Muscular Dystrophy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2480-6.	3.8	99
96	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2011, 29, 2410-2415.	0.8	215
97	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	0.6	89
98	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010, 116, 5501-5506.	0.6	308
99	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	0.6	204
100	Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. <i>Annals of Hematology</i> , 2010, 89, 523-525.	0.8	8
101	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. <i>British Journal of Haematology</i> , 2010, 148, 918-924.	1.2	20
102	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 830-834.	0.8	165
103	Survival Patterns in Patients With Hodgkin's Lymphoma With a Pre-Existing Hospital Discharge Diagnosis of Autoimmune Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 5081-5087.	0.8	14
104	Thrombosis in Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 437-444.	0.9	89
105	Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia. <i>Journal of the National Cancer Institute</i> , 2010, 102, 557-567.	3.0	83
106	Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , 2010, 95, 1216-1220.	1.7	151
107	Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic. <i>Mayo Clinic Proceedings</i> , 2010, 85, 225-230.	1.4	113
108	The Success Story of Targeted Therapy In Chronic Myeloid Leukemia: A Population-Based Study of 3,173 Patients Diagnosed In Sweden 1973-2008. <i>Blood</i> , 2010, 116, 205-205.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. <i>Blood</i> , 2010, 116, 4053-4053.	0.6	0
110	Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2009, 94, 1179-1181.	1.7	14
111	Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden. <i>Journal of Clinical Oncology</i> , 2009, 27, 2073-2080.	0.8	59
112	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , 2009, 125, 2147-2150.	2.3	63
113	Timing of births and endometrial cancer risk in Swedish women. <i>Cancer Causes and Control</i> , 2009, 20, 1441-1449.	0.8	21
114	Highly increased familial risks for specific lymphoma subtypes. <i>British Journal of Haematology</i> , 2009, 146, 91-94.	1.2	85
115	A "pilot" study on air travel and venous thromboembolism. <i>British Journal of Haematology</i> , 2009, 146, 457-459.	1.2	2
116	Increased Risk for Non-Hodgkin Lymphoma in Individuals With Celiac Disease and a Potential Familial Association. <i>Gastroenterology</i> , 2009, 136, 91-98.	0.6	78
117	Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 19-22.	1.4	25
118	Genetics- and Immune-Related Factors in the Pathogenesis of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 23-26.	1.4	16
119	Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. <i>Genome Medicine</i> , 2009, 1, 55.	3.6	7
120	Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 473-478.	1.0	3
121	Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. <i>Blood</i> , 2009, 113, 3666-3672.	0.6	103
122	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	0.6	133
123	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	1.7	95
124	Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 1460-1464.	1.7	21
125	Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. <i>Haematologica</i> , 2009, 94, 1581-1589.	1.7	30
126	Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. <i>Haematologica</i> , 2009, 94, 1259-1265.	1.7	72

#	ARTICLE	IF	CITATIONS
127	Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 647-653.	1.7	113
128	Autoimmunity and risk for Hodgkin's lymphoma by subtype. <i>Haematologica</i> , 2009, 94, 1468-1469.	1.7	28
129	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , 2009, 114, 1872-1872.	0.6	2
130	Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005.. <i>Blood</i> , 2009, 114, 1553-1553.	0.6	3
131	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24%577 first-degree relatives of 11%039 patients with myeloproliferative neoplasms in Sweden. <i>Blood</i> , 2008, 112, 2199-2204.	0.6	226
132	Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. <i>Blood</i> , 2008, 112, 3582-3586.	0.6	170
133	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. <i>Blood</i> , 2008, 112, 3052-3056.	0.6	143
134	Response: More on disease anticipation in familial MPN. <i>Blood</i> , 2008, 112, 2588-2589.	0.6	2
135	Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. <i>Blood</i> , 2008, 112, 3758-3758.	0.6	0
136	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. <i>Journal of Clinical Oncology</i> , 2007, 25, 1993-1999.	0.8	275
137	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. <i>International Journal of Cancer</i> , 2007, 121, 2260-2266.	2.3	104
138	Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden.. <i>Blood</i> , 2007, 110, 680-680.	0.6	4
139	Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.. <i>Blood</i> , 2007, 110, 660-660.	0.6	0
140	Patterns of Venous Thromboembolism (VTE) Following Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM) among 4 Million U.S. Veterans.. <i>Blood</i> , 2006, 108, 4998-4998.	0.6	0
141	Prognosis in Acute Myeloid Leukemia: A Population-Based Study on 5,809 Patients Diagnosed in Sweden 1973-2001.. <i>Blood</i> , 2005, 106, 1845-1845.	0.6	1
142	Epidemiology of hairy cell leukemia in Iceland. <i>The Hematology Journal</i> , 2002, 3, 145-147.	2.0	11